FDA Approves First Targeted Drug To Treat HER2-Low Breast …
WEBJun 5, 2022 · The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK) breast medical oncologist Shanu Modi, who presented the findings at this year’s American Society of Clinical Oncology (ASCO) meeting.
FDA grants accelerated approval to fam-trastuzumab deruxtecan …
WEBOn April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or...
T-DXd Improves Progression-Free Survival in Patients With Breast …
WEBJun 2, 2024 · Fam-trastuzumab deruxtecan-nxki (T-DXd) delayed cancer growth in patients with hormone receptor (HR)-positive, HER2-low or -ultralow metastatic breast cancer that progressed following endocrine therapy, according to findings from the phase III DESTINY-Breast06 trial.
Enhertu Approved for Any HER2-Positive Solid Cancer - NCI
WEBMay 3, 2024 · T-DXd is already approved to treat people with several specific cancers, including breast and stomach. The new approval was based on results from three midsized clinical trials in which treatment with T-DXd shrank tumors (a tumor response) in many people with advanced HER2-positive cancers.
A Closer Look at T-DXd in HER2-Positive Breast Cancer
WEB4 days ago · Those patients that got T-DXd had a progression-free survival of almost 29 months, which is really just unprecedented in the first- or second-line HER2-positive metastatic setting vs about 7 months with T-DM1, so almost a 4-fold improvement in progression-free survival. We have also seen overall survival benefits in …
Trastuzumab Deruxtecan for Metastatic HER2-Low Breast Cancer
WEBJul 5, 2022 · Trastuzumab deruxtecan, also known as T-DXd, “is the first HER2-targeted therapy shown to provide clinically meaningful improvement in progression-free and overall survival compared with standard chemotherapy in people with HER2-low metastatic breast cancer,” Dr. Modi said at the meeting.
T-DXd Earns FDA Breakthrough Therapy Status in HER2-Low …
WEBAug 19, 2024 · The FDA has granted breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) as a treatment for those with unresectable or metastatic hormone receptor (HR)–positive, HER2-low or HER2-ultralow breast cancer, according to a press release from the developer, Daiichi Sankyo. 1
FDA approves fam-trastuzumab deruxtecan-nxki for HER2-low …
WEBOn August 5, 2022, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-low (IHC 1+ or...
T-DXd Maintains Survival Advantage Over Physician’s Choice
WEBMay 16, 2024 · T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer. Trastuzumab deruxtecan demonstrated superior long-term survival and response rates vs ...
T-DXd Yields Longer Overall Survival than T-DM1 in Patients with …
WEBDec 7, 2022 · SAN ANTONIO – Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer, according to updated results from the DESTINY-Breast03 phase III clinical trial presented at …
Skip to content